ライフサイエンスコーパス: seizure disorder

1 tal delay and an intractable infantile-onset seizure disorder.

2 additional subjects, including one without a seizure disorder.

3 al disability, gastroesophageal reflux and a seizure disorder.

4 pharmacologic and surgical treatment of the seizure disorder.

5 relation has on the management of the actual seizure disorder.

6 pharmacologic and surgical treatment of the seizure disorder.

7 suggest that the deaths were related to the seizure disorder.

8 y could help identify novel therapeutics for seizure disorder.

9 sychoses to supernatural causes, followed by seizure disorder.

10 ndicating functional interactions leading to seizure disorder.

11 lepsy is a common and frequently intractable seizure disorder.

12 ted with a two-fold elevated risk for a late seizure disorder.

13 motor and cognitive impairment severity and seizure disorder.

14 f phenytoin, which had been administered for seizure disorder.

15 chiatric symptoms that are concurrent with a seizure disorder.

16 (neurocysticercosis) is a frequent cause of seizure disorders.

17 telemetry of epileptic events in humans with seizure disorders.

18 y prescribed to treat anxiety, insomnia, and seizure disorders.

19 se suggest that SCN8A may also contribute to seizure disorders.

20 interactions in the genomes of patients with seizure disorders.

21 e a therapeutic benefit for the treatment of seizure disorders.

22 cularly vulnerable to dysfunction leading to seizure disorders.

23 her therapeutic approach to the treatment of seizure disorders.

24 some spastic quadriplegic cerebral palsy and seizure disorders.

25 e of the pump in human neurodegenerative and seizure disorders.

26 genetic involvement of GABA(A) receptors in seizure disorders.

27 in investigations of the pathophysiology of seizure disorders.

28 nderstanding of the pathophysiology of human seizure disorders.

29 of therapeutic potential in the treatment of seizure disorders.

30 epileptic drugs have been developed to treat seizure disorders.

31 ion of structural abnormalities that underly seizure disorders.

32 , perinatal complications (4.34, 3.21-5.81), seizure disorders (2.90, 2.24-3.77), and house status (0

33 tal retardation 1.9% versus 1.3% (1.48); and seizure disorders 4.0% versus 1.6% (2.00).

34 Transgenic mice also had a grand mal seizure disorder accompanied by a corresponding dysplasi

35 ific neurodevelopmental delay with co-morbid seizure disorder accounting for 33.3%, 14.8%, 18.5%, 7.4

36 Epilepsy, a recurrent seizure disorder affecting 1% of the population, can be

37 Current drugs for the treatment of seizure disorders, although effective in many patients,

38 isations was 0.89 (95% CI, 0.86 to 0.93) for seizure disorder and 0.32 (95% CI 0.31 to 0.34) for TGA.

39 articipants, one with a pre-existing complex seizure disorder and another who experienced oral surger

40 nsporter KCC2 generates mice with a profound seizure disorder and confirms the central role of this t

41 Comorbid conditions identified were seizure disorder and obesity (2 cases each).

42 /- mice manifest two key phenotypes: a fatal seizure disorder and retarded growth.

43 iable target for therapeutic intervention in seizure disorders and antiepileptogenesis.

44 could be a novel therapeutic target to treat seizure disorders and epilepsy.SIGNIFICANCE STATEMENT We

45 intervention in obesity, metabolic syndrome, seizure disorders and other neurodegenerative diseases,

46 identified pathway in the pathophysiology of seizure disorders and provide evidence for a more genera

47 activity disorder, autism spectrum disorder, seizure disorder) and neurodegenerative (fragile X-assoc

48 d ventriculoperitoneal shunts, 36% developed seizure disorders, and 20% developed severe ototoxicity.

49 Correlating with the seizure disorder are enhanced hippocampal levels of neur

50 Human seizure disorders are a major health concern due to the

51 vere myoclonic epilepsy of infancy, a severe seizure disorder associated with mutations of the sodium

52 that underlie the M-channel cause the human seizure disorder benign familial neonatal convulsions (B

53 Seizure disorders, burn marks, and respiratory problems

54 Temporal lobe epilepsy (TLE) is a common seizure disorder, but the underlying molecular mechanism

55 The concept of epilepsy and seizure disorders caused by autoantibodies to specific n

56 th multiple neurologic conditions, for which seizure disorders comprise the largest group.

57 Seizure disorders debilitate more than 65,000,000 people

58 syndromes, traumatic nerve/muscle injuries, seizure disorders, decreased cognitive ability, poor pul

59 Patients with seizure disorders expressed pain more vocally.

60 Developmental epilepsies are age-dependent seizure disorders for which genetic causes have been inc

61 d speech delay, elevated BMI, short stature, seizure disorders, gait disturbance, and tremors.

62 le spasms, which comprise a severe infantile seizure disorder, have a high morbidity and are difficul

63 In seizure disorders, his name is linked to the first descr

64 Temporal lobe epilepsy is the most prevalent seizure disorder in adults.

65 Febrile seizures are the most common seizure disorder in childhood, associated with a signifi

66 ity, and mutations in these channels cause a seizure disorder in humans.

67 tifying the gene associated with a monogenic seizure disorder in mice, which may ultimately lead to a

68 The fatal seizure disorder in Pcmt1-/- mice can be mitigated but n

69 ctivated glia, in the study and treatment of seizure disorders in humans.

70 The emergence of seizure disorders in old age places an increasing burden

71 Epilepsy or seizure disorder is among the least understood chronic m

72 al effects caused by cerebral hemorrhages or seizure disorders, keeps clinicians alert to any improve

73 luding low birth weight, maternal education, seizure disorder, kidney disease duration, and genetical

74 Some encephalitides or seizure disorders once thought idiopathic now seem to be

75 ible to unravel whether CVI is caused by the seizure disorder or increased intracranial pressure or b

76 of the tumour leads to focal or generalised seizure disorders or neurological deficits caused by com

77 fter were done to identify children with new seizure disorders or other neurodisabilities.

78 nsory perception, behavioural abnormalities, seizure disorders, or a combination of these features.

79 Two-thirds of patients had a severe seizure disorder, placing EPG5 within the rapidly expand

80 Seizure disorders present an attractive gene therapy tar

81 We aimed to assess the prevalence of seizure disorders, psychoses, and mental retardation in

82 nts (1 day-25 years), 13 children with other seizure disorders receiving B6 supplementation (1 month-

83 Human seizure disorders represent a heterogeneous collection o

84 n pathogenesis is suggested by high rates of seizure disorder; research has highlighted the role of s

85 neurologic dysfunction in association with a seizure disorder, resulting in a 1-y period of behaviora

86 gical evidence from several animal models of seizure disorder that adenosine possesses endogenous ant

87 double knock-out mice display a progressive seizure disorder that dramatically reduces their median

88 neuronal RNA-binding protein, have a complex seizure disorder that includes both convulsive and non-c

89 Infantile spasms is a severe infantile seizure disorder that is difficult to treat and has a hi

90 s a promising target for further research on seizure disorder therapeutics.

91 been associated with a poor response of the seizure disorder to pharmacotherapy and epilepsy surgery

92 To investigate the etiology of seizure disorders, we have used a group of Drosophila mu

93 Cases with comorbid seizure disorder were excluded from the study.

94 Delayed bone age and seizure disorders were overrepresented in the TTDN1 grou

95 Seizure disorders were reported in 25% of patients, incl

96 7.4, and in serum samples from patients with seizure disorders who were treated with phenytoin or car

97 oside biosynthesis, result in an early-onset seizure disorder with profound motor and cognitive decay

98 most Spnb3(-/-) animals develop a myoclonic seizure disorder with significant reductions of EAAT4, E

99 epilepsies are a heterogeneous collection of seizure disorders with a lifetime expectancy risk rate o

100 ts (n=19) who were in good health except for seizure disorder, with stable anticonvulsant drug levels